Montelukast Glenmark Pharmaceuticals Europe (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Glenmark Pharmaceuticals Europe, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Glenmark Pharmaceuticals Europe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction. - Asthma: provides maintenance therapy that reduces the frequency and severity of asthma attacks. - Allergic rhinitis: relieves nasal congestion, sneezing and itchy eyes associated with seasonal allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing that occurs during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain often reported. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional dry or productive cough. - Sore throat: irritation or pain in the throat. - Nausea: feeling of queasiness. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips or tongue. - Allergic reactions: rash, hives or severe skin eruptions. - Mood changes: depression, anxiety or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin blistering. - Anaphylaxis: life‑threatening systemic allergic response.

Before prescribing Montelukast, clinicians should consider several safety aspects. - Pregnancy: safety not established; use only if clearly needed. - Breastfeeding: unknown excretion; weigh benefits against potential risks. - Drug interactions: review all concomitant medicines for possible effects on montelukast levels. - Renal or hepatic impairment: dose may require adjustment and close monitoring. - Pediatric use: dosing must be individualized by a qualified prescriber. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Ritonavir: can raise montelukast plasma concentrations. - Phenobarbital: may markedly lower montelukast exposure.

Moderate Interactions (Monitor Closely): - Fluconazole: potential increase in montelukast levels. - Carbamazepine: may decrease therapeutic effect. - Warfarin: monitor INR as montelukast could affect anticoagulation.